Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Hematopoietic stem cell transplantation 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Therapy type trends
2.1.4 Indication trends
2.1.5 Application trends
2.1.6 End-user trends
Chapter 3 Hematopoietic Stem Cell Transplantation Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of hematological disorders
3.2.1.2 Rising success rate of transplantation procedures
3.2.1.3 Increasing number of geriatric patients
3.2.1.4 Advancements in HSCT techniques
3.2.1.5 Increasing awareness among physicians and patients about the benefits of HSCT
3.2.1.6 Expanding stem cell donor registries
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of HSCT procedure
3.2.2.2 Adverse effects associated with the transplants
3.2.2.3 Availability of alternative therapies
3.2.2.4 Disparities in reimbursement policies and insurance coverage for HSCT
3.2.2.5 Difficulty associated with finding donors
3.3 Growth potential analysis
3.3.1 By therapy type
3.3.2 By indication
3.3.3 By application
3.3.4 By end-user
3.3.5 By region
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Therapy Type (USD Million)
5.1 Key trends, by therapy type
5.2 Autologous transplant therapy
5.3 Allogenic transplant therapy
Chapter 6 Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Indication (USD Million)
6.1 Key trends, by indication
6.2 Lymphoproliferative disorders
6.2.1 Non-Hodgkin lymphoma
6.2.2 Hodgkin lymphoma
6.2.3 Plasma cell disorders
6.2.4 Other lymphoproliferative disorders
6.3 Leukemia
6.3.1 Acute myeloid leukemia
6.3.2 Acute lymphatic leukemia
6.3.3 Myelodysplastic syndrome
6.3.4 Other leukemia types
6.4 Nonmalignant disorders
6.4.1 Bone marrow failure
6.4.2 Hemoglobinopathies
6.4.3 Other nonmalignant disorders
Chapter 7 Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Bone marrow stem cell transplant
7.3 Peripheral blood stem cell transplant
7.4 Cord blood transplant
Chapter 8 Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By End-user (USD Million)
8.1 Key trends, by end-user
8.2 Hospitals
8.3 Specialty centers
8.4 Other end-users
Chapter 9 Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Pluristem Therapeutics Inc.
10.2 Sanofi
10.3 Taiga Biotechnologies, Inc.
10.4 CellGenix GmbH
10.5 Novartis AG
10.6 Regen Biopharma Inc.
10.7 Kiadis Pharma
10.8 Marker Therapeutics, Inc.
10.9 Escape Therapeutics, Inc.
10.10 GlaxoSmithKline plc
10.11 Merck KGaA
10.12 Bluebird Bio, Inc.
10.13 Talaris Therapeutics
